Patent ID: 11866725
Assignee: NOVARTIS AG
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 22:
23. A lentiviral transfer vector of claim 22 comprising, from 5′ to 3′, one or more of the following elements in operable association:
(a) a CMV promoter,
(b) an LTR R region,
(c) an LTR U5 region,
(d) a primer binding site (PBS),
(e) a packaging signal (psi) comprising a major splice donor site (SD),
(f) a partial gag sequence consisting of 150-250 nucleotides,
(g) a partial env sequence consisting of a sequence having at least 95% sequence identity to SEQ ID NO: 60,
(h) a Rev-response element (RRE),
(i) a partial env sequence comprising splice acceptor site (SA7) and consisting of a sequence having at least 95% sequence identity to SEQ ID NO: 64,
(j) a central polypurine tract (cPPT) comprising a splice acceptor site (SA1),
(k) an EF1a promoter,
(l) a gene encoding EGFP and/or a heterologous nucleic acid sequence,
(m) a post-transcriptional regulatory element, which optionally comprises a woodchuck hepatitis virus PRE (WPRE) or a hepatitis B virus isolate bba6 PRE (HPRE),
(n) an LTR R region,
(o) an LTR U5 region,
(p) an SV40 polyA tail,
(q) a kanamycin resistance gene (nptII), and
(r) a pUC origin of replication.